Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review

@inproceedings{Camicia2015NovelDT,
  title={Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review},
  author={Rosalba Camicia and Hans Christian Winkler and Paul O. Hassa},
  booktitle={Molecular Cancer},
  year={2015}
}
Diffuse large B-cell lymphoma (DLBCL) is a clinically heterogeneous lymphoid malignancy and the most common subtype of non-Hodgkin’s lymphoma in adults, with one of the highest mortality rates in most developed areas of the world. More than half of DLBLC patients can be cured with standard R-CHOP regimens, however approximately 30 to 40 % of patients will develop relapsed/refractory disease that remains a major cause of morbidity and mortality due to the limited therapeutic options. Recent… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 4 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 26 extracted citations

A Review of Autologous Stem Cell Transplantation in Lymphoma.

Current hematologic malignancy reports • 2017

References

Publications referenced by this paper.
Showing 1-10 of 640 references

Host immune response in B-cell lymphomas: friend or foe?

Archivum Immunologiae et Therapiae Experimentalis • 2008
View 20 Excerpts
Highly Influenced

DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein

GE Winter, DL Buckley, +3 authors S Dhe-Paganon
2015
View 6 Excerpts
Highly Influenced

Phase IIa Trial of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas

SJ Schuster, J Svoboda, +3 authors GD Shah
American Society of Clinical Oncology Annual Meeting • 2015
View 4 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…